BioSpace News Archive

Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for proceeds of approximately $50.0 million, before deducting estimated offering expenses payable by Homology.

In September 2020 biotech start-up COVIMRO Ltd demonstrated the effectiveness of its food-grade compound, Covimro, against Coronavirus.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that it has been granted an exclusive sublicense to technology related to the use of novel and proprietary central nervous system (CNS) homing peptides for the therapeutic treatment of neuroinflammatory disease in cancer patients.

The $2.5 Million USD Multi-Year Partnership Builds Capacity to Provide Pediatric Heart Surgery to 10,000 Children and Trains 10,000 Health Workers in Brazil, India, and China.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced three corporate governance additions to further position the organization for continued growth and advancing its mission to develop and commercialize software as treatments.

World-Class MedTech R&D Hub to Drive Community Connections, Employee Wellness, Global Collaboration and Medical Telecollaboration Advancements

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving the way for escalation of the dose in Cohort 2

Endevica Bio (formerly known as Tensive Controls Inc.), a company developing best-in-class peptide drug candidates with better safety and efficacy properties, has signed an agreement with Wuxi AppTec to begin toxicology studies for TCMCB07, its investigational therapeutic for cancer cachexia.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 “Don Clifton Strengths-Based Culture Award” from Gallup.

Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve outcomes and costs associated with patient treatment as they transition to value-based care.